What Is Ipamorelin? Growth Hormone Secretagogue Research Guide

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue originally identified during medicinal-chemistry research into GHRP-type receptor agonists. It is also referenced in research records as NNC-26-0161 or NNC-260161. Unlike GHRH analogues such as Modified GRF (1-29) and tesamorelin, ipamorelin belongs to the growth-hormone-secretagogue/ghrelin-receptor research pathway.

The distinction between those two signalling systems is important. Both can influence growth-hormone release in experimental settings, but they engage different receptor biology and should not be described as interchangeable compounds.

What Is Ipamorelin?

Ipamorelin was described in a 1998 pharmacology paper as a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The molecule emerged from a broader chemistry programme designed to identify potent growth-hormone secretagogues with greater selectivity for GH release than earlier members of the GHRP family.

Its compact five-residue structure contains non-standard amino-acid chemistry, illustrating how peptide design can use stereochemistry and unnatural residues to alter receptor interaction, enzymatic stability and molecular conformation.

Ipamorelin and the Growth-Hormone-Secretagogue Receptor

The receptor historically described as the growth-hormone-secretagogue receptor is now closely associated with GHSR1a, the ghrelin receptor. It is a G-protein-coupled receptor involved in endocrine and metabolic signalling and is distinct from the GHRH receptor.

Ipamorelin was developed as an agonist within this secretagogue pathway. Research therefore examines it in the context of GHSR signalling, pituitary GH release and related neuroendocrine mechanisms rather than as a modified GHRH molecule.

Why Ipamorelin Was Described as Selective

The original Raun and colleagues study compared ipamorelin with earlier growth-hormone-releasing peptides. In the preclinical systems tested, ipamorelin produced potent GH release while showing less stimulation of ACTH and cortisol than GHRP-2 and GHRP-6. The authors described it as the first GHRP-receptor agonist with selectivity for GH release resembling that of GHRH under their experimental conditions.

That wording should be interpreted carefully. “Selective” does not mean that a molecule has only one possible biological effect in every organism or experimental system. Selectivity is always relative to the assays, concentrations, species and endpoints measured.

Human Pharmacokinetic and Pharmacodynamic Research

Ipamorelin progressed into controlled human research. A randomized dose-escalation study in healthy male volunteers measured both circulating ipamorelin and growth-hormone responses following intravenous infusion.

The study reported dose-proportional pharmacokinetics and a terminal half-life of approximately two hours under the specific intravenous study conditions. Growth-hormone release appeared as an episodic response, with a measured peak followed by decline toward baseline.

These data provide genuine human PK/PD evidence for ipamorelin. However, the exact values should remain tied to the study design and route used. They should not be converted into consumer dosing or administration claims.

Ipamorelin Is Not a GHRH Analogue

This is one of the most important distinctions for researchers. Ipamorelin and CJC-1295 No DAC can both appear in discussions of growth-hormone research, but their primary receptor pathways differ:

  • Ipamorelin: growth-hormone-secretagogue/ghrelin receptor pathway.
  • CJC-1295 No DAC / Modified GRF (1-29): GHRH-receptor pathway.
  • Tesamorelin: GHRH-receptor pathway.

Separating these mechanisms improves experimental interpretation and prevents a blend containing two classes from being incorrectly described as one peptide acting through one receptor.

Evidence Beyond GH Release

Ipamorelin has been investigated in additional experimental contexts, including gastrointestinal motility research and postoperative ileus. Importantly, not every clinical hypothesis has produced positive results.

A multicentre randomized placebo-controlled Phase II trial evaluated ipamorelin in postoperative ileus. The study is useful from an evidence-quality perspective because it demonstrates that mechanistic or preclinical rationale does not guarantee clinical efficacy. High-quality research content should therefore report negative or neutral findings alongside positive mechanistic observations.

Peptide Chemistry and Analytical Identity

Because ipamorelin is a small synthetic pentapeptide containing unusual residues, analytical identity should be based on more than appearance. A robust research-material record may use chromatographic purity assessment together with mass-based identity information.

HPLC

Reverse-phase HPLC can separate a principal ipamorelin peak from detectable impurities under a defined method. Peak-area purity is useful for batch assessment, but the number does not by itself confirm exact molecular identity.

LC-MS

LC-MS can add molecular-mass information and can support identity assessment. Mass-spectrometric research has also been used to investigate ipamorelin-related analytes and metabolites, illustrating the value of high-resolution analytical techniques for short synthetic peptides.

For general analytical background, see Understanding HPLC Purity.

What Does NNC-26-0161 Mean?

NNC-26-0161 is a research/development identifier associated with ipamorelin. Development codes are useful when searching older scientific literature because generic names can be adopted later in a compound’s history.

A development identifier is not a separate peptide. Where the identity is correctly established, NNC-26-0161 and ipamorelin refer to the same research compound.

Batch Verification and COA Review

A Certificate of Analysis should connect the physical research material to its production batch. For ipamorelin, useful documentation may include the product identity, batch number, nominal quantity, HPLC data, mass-related identity information and test date where available.

The batch number on the vial should correspond with the documentation being reviewed. A generic ipamorelin report from another batch should not be treated as proof of the current material.

See Certificate of Analysis Library, Certificate of Analysis Explained and Quality Assurance.

Evidence Limitations

Ipamorelin has more human PK/PD information than many peptides circulating in the research-material market, but that does not mean every popular claim about it has been clinically established. The evidence base includes receptor pharmacology, preclinical experiments, early human pharmacology and limited clinical-development studies. It does not justify converting research findings into broad therapeutic or performance claims.

When reading literature, researchers should distinguish:

  • in-vitro receptor or cell studies;
  • animal experiments;
  • healthy-volunteer PK/PD studies;
  • controlled clinical outcome studies; and
  • unsupported marketplace claims.

Frequently Asked Questions

What is another research name for Ipamorelin?

NNC-26-0161 and NNC-260161 are development identifiers associated with ipamorelin.

How many amino-acid residues does Ipamorelin contain?

Ipamorelin is a synthetic pentapeptide, meaning it contains five residues.

Does Ipamorelin act at the GHRH receptor?

It is primarily classified as a growth-hormone-secretagogue/ghrelin-receptor agonist rather than a GHRH analogue.

Is Ipamorelin the same as CJC-1295 No DAC?

No. They are different peptides associated with different receptor pathways.

Has Ipamorelin been studied in humans?

Yes. Controlled healthy-volunteer pharmacokinetic/pharmacodynamic research has been published, and a Phase II postoperative-ileus study was also conducted. Those studies do not establish every claim made about the compound online.

Does HPLC prove Ipamorelin identity?

No. HPLC helps assess chromatographic purity. Complementary mass-based or other identity methods can provide additional evidence.

Selected Scientific References

Related Research Resources

This article is provided for laboratory, analytical and scientific education only. It does not provide dosing, administration, injection, therapeutic or personal-use guidance.

Back to blog